Acellular collagen-glycosaminoglycan matrix promotes functional recovery in a rat model of volumetric muscle loss.

IF 2.4 4区医学 Q4 CELL & TISSUE ENGINEERING Regenerative medicine Pub Date : 2023-08-01 DOI:10.2217/rme-2023-0060

Christina Zhu, Mehran Karvar, Daniel J Koh, Karina Sklyar, Yori Endo, Jacob Quint, Mohamadmahdi Samandari, Ali Tamayol, Indranil Sinha

引用次数: 1

Abstract

Aim: Volumetric muscle loss (VML) is a composite loss of skeletal muscle, which heals with fibrosis, minimal muscle regeneration, and incomplete functional recovery. This study investigated whether collagen-glycosaminoglycan scaffolds (CGS) improve functional recovery following VML. Methods: 15 Sprague-Dawley rats underwent either sham injury or bilateral tibialis anterior (TA) VML injury, with or without CGS implantation. Results: In rats with VML injuries treated with CGS, the TA exhibited greater in vivo tetanic forces and in situ twitch and tetanic dorsiflexion forces compared with those in the non-CGS group at 4- and 6-weeks following injury, respectively. Histologically, the VML with CGS group demonstrated reduced fibrosis and increased muscle regeneration. Conclusion: Taken together, CGS implantation has potential augment muscle recovery following VML.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

脱细胞胶原-糖胺聚糖基质促进大鼠体积性肌肉损失模型的功能恢复。

目的:体积性肌肉损失(VML)是骨骼肌的一种复合损失，其愈合伴有纤维化、最小肌肉再生和不完全功能恢复。本研究探讨胶原-糖胺聚糖支架(CGS)是否能改善VML后的功能恢复。方法:15只Sprague-Dawley大鼠分别接受假损伤或双侧胫骨前肌(TA) VML损伤，植入或不植入CGS。结果:在损伤后4周和6周，与非CGS组相比，CGS治疗的VML损伤大鼠TA表现出更大的体内强直力和原位抽搐和强直背屈力。组织学上，VML加CGS组纤维化减少，肌肉再生增加。结论:CGS植入有增强VML术后肌肉恢复的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Regenerative medicine 医学-工程：生物医学

CiteScore

4.20

自引率

3.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization. Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community. Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.